PO-02-161 EFFECTS OF SGLT2I ON REDUCING DEMENTIA RISKS IN ATRIAL FIBRILLATION PATIENTS WITH DIABETES : A NATIONWIDE COHORT

It is unknown whether sodium-glucose cotransporter-2 inhibitor (SGLT2i) reduces new-onset cognitive dysfunction in atrial fibrillation (AF) patients with diabetes. The purpose of this study was to investigate SGLT2i the risk dementia among AF who have In study, we identified based on Taiwanese National Health Insurance Research Database (2013-2014). total, 17925 under 18 years old without prior history were studied. Among patients, 1374 prescribed for SGLT2i. By using same propensity-score, group matched 1:2 (N=2747). Dementia events followed through end 2019. Subtypes investigated competing models. During a follow-up period 5 years, total 354 occurred during follow-up. diabetes receiving SGLT2i, number significantly decreased (HR: 0.71, 95% CI: 0.56-0.90). As result use, vascular only 0.42, 0.22-0.79), especially older people (over 65 old, HR: 0.28, 0.08-0.94; P-value interaction = 0.06), but not (65 0.77, 0.59-1.01), Neither rhythm control therapy nor medication reduced risk. There associated use reducing effects factors outcomes may improve 5-year outcomes.